The Governors of the University of Calgary
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- Private
- Established
- 1966-04-29
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.ucalgary.ca
Caregiving in Advanced PD: A Tailored Support Group
Not Applicable
Not yet recruiting
- Conditions
- Parkinson's Disease and Parkinsonism
- Interventions
- Behavioral: Tailored Support Group
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 40
- Registration Number
- NCT06074393
- Locations
- 🇨🇦
Health Science Centre, University of Calgary, Calgary, Alberta, Canada
Building Emotional Awareness and Mental Health in Parenting (BEAM)
Not Applicable
Recruiting
- Conditions
- Parent Mental HealthChild Mental HealthParentingChild Development
- Interventions
- Behavioral: Building Emotion Awareness and Mental Health (BEAM)
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 240
- Registration Number
- NCT06046989
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
🇨🇦University of British Columbia, Vancouver, British Columbia, Canada
ATTACH™ Online Platform: Helping Children Vulnerable to Early Adversity
Not Applicable
Recruiting
- Conditions
- Parent-Child Relations
- Interventions
- Behavioral: ATTACH™ Online Platform Parenting Program
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 160
- Registration Number
- NCT05994027
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 128
- Registration Number
- NCT05995769
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
Testing of a System for Remote Ischemic Conditioning in Cerebral Small Vessel Disease and Pre-hospital Stroke Care
Phase 2
- Conditions
- Ischemic StrokeStroke, AcuteCerebral Small Vessel Ischemic DiseaseVascular Cognitive ImpairmentCerebral Small Vessel Diseases
- Interventions
- Device: Remote ischemic conditioning (RIC) progammable device
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 24
- Registration Number
- NCT05967728
- Locations
- 🇨🇦
Foothills Medical Centre, Calgary, Alberta, Canada
Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents
Not Applicable
Recruiting
- Conditions
- Depression in Adolescence
- Interventions
- Other: GLAD-PC guided dosingOther: Pharmacogenetic-guided dosing
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 452
- Registration Number
- NCT05965401
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
Goal-Directed Therapy Following Cardiac Surgery
Not Applicable
Not yet recruiting
- Conditions
- Surgery
- Interventions
- Device: Goal-directed therapy
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 100
- Registration Number
- NCT05964374
Strength Training for Osteoporosis Prevention During Early Menopause
Not Applicable
Active, not recruiting
- Conditions
- Bone Loss, Age-relatedOsteoporosisMusculoskeletal DiseasesBone Loss
- Interventions
- Other: Resistance Training
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 40
- Registration Number
- NCT05961371
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
Phase 4
Recruiting
- Conditions
- Crohn Disease
- Interventions
- Biological: TNFa Antagonist - InfliximabBiological: Anti-IL12/23 or anti-IL23 - UstekinumabBiological: Anti-integrin - Vedolizumab IVBiological: TNFa Antagonist - AdalimumabBiological: Anti-integrin - Vedolizumab IV and SCBiological: Anti-IL12/23 or anti-IL23 - Risankizumab
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 297
- Registration Number
- NCT05928039
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
Incidence and Predictors of Bleeding During and Following ERCP
Completed
- Conditions
- Bleeding UGI (During or Post-ERCP)
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 5872
- Registration Number
- NCT05929404
- Locations
- 🇨🇦
Peter Lougheed Center, Calgary, Alberta, Canada
© Copyright 2025. All Rights Reserved by MedPath